Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Cash & Equivalents (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Cash & Equivalents data on record, last reported at $30.1 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 34.93% year-over-year to $30.1 million; the TTM value through Dec 2025 reached $30.1 million, down 34.93%, while the annual FY2025 figure was $30.1 million, 34.93% down from the prior year.
  • Cash & Equivalents reached $30.1 million in Q4 2025 per VRCA's latest filing, up from $21.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $84.3 million in Q3 2023 and bottomed at $15.4 million in Q2 2025.
  • Average Cash & Equivalents over 5 years is $39.1 million, with a median of $33.4 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 159.6% in 2023, then crashed 72.72% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $15.8 million in 2021, then surged by 117.58% to $34.3 million in 2022, then skyrocketed by 102.92% to $69.5 million in 2023, then tumbled by 33.38% to $46.3 million in 2024, then plummeted by 34.93% to $30.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $30.1 million in Q4 2025, $21.1 million in Q3 2025, and $15.4 million in Q2 2025.